

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2019

https://marketpublishers.com/r/R42A0816687EN.html

Date: April 2019 Pages: 104 Price: US\$ 3,500.00 (Single User License) ID: R42A0816687EN

Abstracts

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2019

SUMMARY

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Metastatic



Breast Cancer, Solid Tumor, Esophageal Cancer, Head And Neck Cancer, Lung Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Bile Duct Cancer (Cholangiocarcinoma), Biliary Tumor, Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary), Endometrial Cancer, Epithelial Tumor, Hypopharyngeal Cancer, Laryngeal Cancer, Lung Adenocarcinoma, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Thyroid Cancer, Paranasal Sinus And Nasal Cavity Cancer, Sarcomas, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H1 2019, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene



Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Receptor



Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Therapeutics Development

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Companies Involved in Therapeutics Development

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

- Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 (Contd..1), H1 2019 Products under Development by Companies, H1 2019 (Contd..2), H1 2019 Products under Development by Companies, H1 2019 (Contd..3), H1 2019 Products under Development by Companies, H1 2019 (Contd..4), H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by Aslan Pharmaceuticals Ltd, H1 2019 Pipeline by AstraZeneca Plc, H1 2019 Pipeline by AVEO Pharmaceuticals Inc, H1 2019 Pipeline by Celldex Therapeutics Inc, H1 2019 Pipeline by Etubics Corp, H1 2019 Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019 Pipeline by Hummingbird Bioscience Pte Ltd, H1 2019 Pipeline by Imugene Ltd, H1 2019 Pipeline by MediaPharma SRL, H1 2019 Pipeline by Merus NV, H1 2019 Pipeline by Novartis AG, H1 2019 Pipeline by SunRock Biopharma SL, H1 2019 Pipeline by Symphogen A/S, H1 2019 Pipeline by Taiho Pharmaceutical Co Ltd, H1 2019 Pipeline by Takis Srl, H1 2019 Pipeline by XuanZhu Pharma Co Ltd, H1 2019 Dormant Products, H1 2019 Dormant Products, H1 2019 (Contd..1), H1 2019 Dormant Products, H1 2019 (Contd..2), H1 2019 Dormant Products, H1 2019 (Contd..3), H1 2019



Dormant Products, H1 2019 (Contd..4), H1 2019 Discontinued Products, H1 2019 Discontinued Products, H1 2019 (Contd..1), H1 2019 Discontinued Products, H1 2019 (Contd..2), H1 2019



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

COMPANIES MENTIONED

Aslan Pharmaceuticals Ltd AstraZeneca Plc **AVEO Pharmaceuticals Inc Celldex Therapeutics Inc Etubics** Corp Hanmi Pharmaceuticals Co Ltd Hummingbird Bioscience Pte Ltd Imugene Ltd MediaPharma SRL Merus NV Novartis AG SunRock Biopharma SL Symphogen A/S Taiho Pharmaceutical Co Ltd Takis Srl XuanZhu Pharma Co Ltd



I would like to order

Product name: Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) -Pipeline Review, H1 2019

Product link: https://marketpublishers.com/r/R42A0816687EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/R42A0816687EN.html</u>